BEAM vs. CRSP, DNLI, EDIT, NTLA, TWST, VCYT, VERV, ROIV, ELAN, and RVMD
Should you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Twist Bioscience (TWST), Veracyte (VCYT), Verve Therapeutics (VERV), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Revolution Medicines (RVMD). These companies are all part of the "medical" sector.
Beam Therapeutics vs. Its Competitors
Beam Therapeutics (NASDAQ:BEAM) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.
Beam Therapeutics has a net margin of -609.24% compared to CRISPR Therapeutics' net margin of -1,023.64%. CRISPR Therapeutics' return on equity of -20.08% beat Beam Therapeutics' return on equity.
Beam Therapeutics has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500.
Beam Therapeutics presently has a consensus price target of $48.75, indicating a potential upside of 138.39%. CRISPR Therapeutics has a consensus price target of $71.75, indicating a potential upside of 30.24%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.
99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 3.5% of Beam Therapeutics shares are owned by insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
CRISPR Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, CRISPR Therapeutics had 7 more articles in the media than Beam Therapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 6 mentions for Beam Therapeutics. CRISPR Therapeutics' average media sentiment score of 1.00 beat Beam Therapeutics' score of 0.47 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.
Summary
Beam Therapeutics beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Beam Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beam Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BEAM) was last updated on 7/18/2025 by MarketBeat.com Staff
Free BEAM Stock Alerts